<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03294278</url>
  </required_header>
  <id_info>
    <org_study_id>IRCCSDonato Brugada-randomized</org_study_id>
    <nct_id>NCT03294278</nct_id>
  </id_info>
  <brief_title>Epicardial Ablation in Brugada Syndrome to Prevent Sudden Death</brief_title>
  <official_title>Epicardial Ablation in Brugada Syndrome in the Prevention of Sudden Cardiac Death. A Randomized Prospective Follow-up Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Policlinico S. Donato</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS Policlinico S. Donato</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A total of 150 patients will be randomized to perform catheter ablation or not in a 2:1
      fashion in selected patients with Brugada-related symptoms (Ablation+ICD arm 105 patients vs
      ICD only 45 patients).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main purpose of this trial is to develop evidence-based curative treatment with optimal
      net benefit for patients with Brugada syndrome. As recent non-randomized pilot studies and
      scarce case reports documented the potential benefit of epicardial ablation, patients in this
      trial will be randomized to epicardial catheter ablation of the regions exhibiting abnormally
      prolonged and fragmented electrograms in the right ventricular outflow tract plus continued
      implanted cardioverter defibrillator therapy (ablation arm) or continued implanted
      cardioverter defibrillator therapy (control arm).

      Survival from any ventricular arrhythmia (VA) recurrence will be considered as primary
      endpoint.

      A projected 150 patients will be enrolled and randomized to receive ablation or not in a 2:1
      fashion (Ablation+ICD arm 105 patients vs ICD only 45 patients).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 10, 2017</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival from any VA recurrence will be considered as primary endpoint</measure>
    <time_frame>2 years after ablation</time_frame>
    <description>NO ventricular arrhythmia recurrence</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Ventricular Arrhythmias and Cardiac Arrest</condition>
  <arm_group>
    <arm_group_label>Ablation plus ICD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Epicardial ablation by radio-frequency</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ICD alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Implantation of ICD</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ablation plus ICD</intervention_name>
    <description>Defibrillator, radio-frequency catheter ablation</description>
    <arm_group_label>Ablation plus ICD</arm_group_label>
    <arm_group_label>ICD alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients affected by Brugada Syndrome diagnosed according to 2013 HRS/EHRA/APHRS

          -  Consensus document criteria

          -  The patient received at least 1 appropriate ICD shock.

          -  Documentation of any previous ventricular arrhythmia (VA) in the form of VT,
             non-sustained VT, non-sustained VF, RVOT PVC with a daily burden &gt;10000;

          -  Age â‰¥ 18;

          -  Willingness to attend follow-up examinations;

          -  Written informed consent for participation in the trial.

        Exclusion Criteria:

          -  A patient who does not meet inclusion criteria;

          -  Pregnancy or breast-feeding (which would exclude an ablation procedure);

          -  Contraindications to general anesthesia or epicardial ablation;

          -  Life expectancy &lt; 12 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlo Pappone, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS Policlinico San Donato Milan, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carlo Pappone, MD</last_name>
    <phone>+39 02 52774260</phone>
    <email>carlo.pappone@af-ablation.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>IRCCS Policlinico S. Donato</name>
      <address>
        <city>San Donato Milanese</city>
        <state>Milano</state>
        <zip>20097</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlo Pappone, MD, PhD</last_name>
      <phone>00390252774260</phone>
      <email>carlo.pappone@af-ablation.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2017</study_first_submitted>
  <study_first_submitted_qc>September 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2017</study_first_posted>
  <last_update_submitted>October 18, 2017</last_update_submitted>
  <last_update_submitted_qc>October 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Policlinico S. Donato</investigator_affiliation>
    <investigator_full_name>Carlo Pappone</investigator_full_name>
    <investigator_title>Chief of Arrhythmology Department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Arrest</mesh_term>
    <mesh_term>Brugada Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

